Abstract
Reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is a membrane-anchored glycoprotein that negatively regulates the activities of matrix metalloproteinases (MMPs) and inhibits tumor invasion, metastasis, and angiogenesis. RECK is essential for normal development and is a key mediator of tissue remodeling and stabilization of tissue architechture. Downregulation of RECK documented in a wide range of malignant neoplasms correlates with poor prognosis, and tumor metastasis. The RECK gene is a common negative target for oncogenic signals that act on the Sp1-binding site of the RECK promoter. Both natural and synthetic agents have been identified as upregulators of RECK. Several strategies have been proposed to enhance RECK expression including forced expression of RECK, use of mimetics, recombinant peptides, microRNA antagonists, and gene therapy. Upregulation of RECK could be a valuable therapeutic option to improve prognosis and block tumor progression. This review addresses the potential value of RECK as a prognostic marker and as a molecular target for cancer therapy.
Keywords: Angiogenesis, Histone deacetylase, Invasion, Matrix metalloproteinases, RECK, Sp1 protein, Tissue inhibitor of matrix metalloproteinases, cytotrophoblasts, syncytiotrophoblasts, glycosylphosphatidylinositol.
Anti-Cancer Agents in Medicinal Chemistry
Title:RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Volume: 12 Issue: 7
Author(s): Siddavaram Nagini
Affiliation:
Keywords: Angiogenesis, Histone deacetylase, Invasion, Matrix metalloproteinases, RECK, Sp1 protein, Tissue inhibitor of matrix metalloproteinases, cytotrophoblasts, syncytiotrophoblasts, glycosylphosphatidylinositol.
Abstract: Reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is a membrane-anchored glycoprotein that negatively regulates the activities of matrix metalloproteinases (MMPs) and inhibits tumor invasion, metastasis, and angiogenesis. RECK is essential for normal development and is a key mediator of tissue remodeling and stabilization of tissue architechture. Downregulation of RECK documented in a wide range of malignant neoplasms correlates with poor prognosis, and tumor metastasis. The RECK gene is a common negative target for oncogenic signals that act on the Sp1-binding site of the RECK promoter. Both natural and synthetic agents have been identified as upregulators of RECK. Several strategies have been proposed to enhance RECK expression including forced expression of RECK, use of mimetics, recombinant peptides, microRNA antagonists, and gene therapy. Upregulation of RECK could be a valuable therapeutic option to improve prognosis and block tumor progression. This review addresses the potential value of RECK as a prognostic marker and as a molecular target for cancer therapy.
Export Options
About this article
Cite this article as:
Nagini Siddavaram, RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review), Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/187152012802650237
DOI https://dx.doi.org/10.2174/187152012802650237 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evolution of the Strategies for Screening and Identifying Human Tumor Antigens
Current Protein & Peptide Science Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs A Feature-Free 30-Disease Pathological Brain Detection System by Linear Regression Classifier
CNS & Neurological Disorders - Drug Targets Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Stem Cells as Delivery Vehicles for Oncolytic Adenoviral Virotherapy
Current Gene Therapy Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Hypoxia-Inducible Factor-1 as Regulator of Angiogenesis in Rheumatoid Arthritis - Therapeutic Implications
Current Medicinal Chemistry Design of Magnetic Nanoparticles-Assisted Drug Delivery System
Current Pharmaceutical Design A Discussion Regarding the Application of the Hertz Contact Theory on Biological Samples in AFM Nanoindentation Experiments
Micro and Nanosystems Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins
Anti-Cancer Agents in Medicinal Chemistry Tumor Suppression by DNA Base Excision Repair
Mini-Reviews in Medicinal Chemistry Occurrence and Biological Activities of Eremophilane-type Sesquiterpenes
Mini-Reviews in Medicinal Chemistry Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry Anesthetic Cardioprotection in Relation to Mitochondria: Basic Science
Current Pharmaceutical Design Natural Products as Anti-Invasive and Anti-Metastatic Agents
Current Medicinal Chemistry Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity
Current Medicinal Chemistry The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications
Current Medicinal Chemistry Biomedical Application of Polymers: A Case Study of Non-CNS Drugs Becoming CNS Acting Drugs
Central Nervous System Agents in Medicinal Chemistry